Rx Medicare

Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced that the company’s SynCon? H1N1 influenza DNA vaccines achieved protection against current circulating swine origin influenza A/H1N1 viruses in animal studies.

Read More…

Related Posts

• Inovio Biomedical, National Microbiology Laboratory, And University Of Pennsylvania To Evaluate Candidate DNA Vaccines Against “Swine” Influenza A
• Inviragen Researching Vaccines To Protect Against Pandemic And Seasonal Influenza Viruses
• A(H1N1) Influenza Pandemic: Sanofi Pasteur’s Global Response
• NanoViricides Presents FluCide™ Animal Study Data At Influenza Congress – Now Improved Substantially And Vastly Superior To Current Treatment
• European Medicines Agency Recommends Authorisation Of Two Vaccines For Influenza Pandemic (H1N1) 2009
• Tamiflu Remains Fully Effective Against 94 Percent Of Circulating Influenza Viruses In Europe
• The Pathogenicity of Pandemic Influenza Viruses
• Poor Evidence For Effectiveness Of Influenza Vaccines In Elderly
• European Medicines Agency Updates On Pandemic Influenza
• Statement By The Welsh Assembly Government On Latest Developments In Respect Of The Influenza A (H1N1) Swine Flu Pandemic
• SinoFresh Nasal Spray Achieves Positive Results Against H1N1 (Swine Flu) Virus In Initial Pilot Animal Study
• European Medicines Agency Reaffirms Efficacy And Safety Of H1N1v Pandemic Vaccines
• CSL Biotherapies Obtains FDA Licensure For Use Of Its Thimerosal-Free Pandemic Influenza A (H1N1) 2009 Monovalent Vaccine In Children
• NanoViricides, Inc. To Present Anti-Influenza Drug Candidate FluCide™ Studies At The Influenza Congress 2009
• Could Vaccination For Children Against Seasonal Flu Stop Immunity Developing Against Pandemic Strains?

Tags: against, ah1n1, animal, biomedical, current, demonstrate, efficacy, influenza, inovio, pandemic, protection, studies, universal, vaccines, viruses

This entry was posted on Friday, July 31st, 2009 at 11:07 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.